Efficacy classification of modern therapies in multiple sclerosis

The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines. Therapies were classified by...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of comparative effectiveness research 2021-04, Vol.10 (6), p.495-507
Hauptverfasser:	Samjoo, Imtiaz A, Worthington, Evelyn, Drudge, Christopher, Zhao, Melody, Cameron, Chris, Häring, Dieter A, Stoneman, Dee, Klotz, Luisa, Adlard, Nicholas
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Bans cladribine Cladribine - therapeutic use Classification Clinical trials disease-modifying therapy Drug dosages Humans Meta-analysis Monoclonal antibodies Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis, Relapsing-Remitting - drug therapy network meta-analysis Neurology ocrelizumab ofatumumab ozanimod Patients Recurrence relapsing multiple sclerosis treatment guidelines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!